First patient dosed in the TiNivo clinical trial investigating a combination of tivozanib plus nivolumab

The first patient has been dosed in the TiNivo trial: a Phase I/II clinical trial investigating tivozanib, a VEGF tyrosine kinase inhibitor, in combination with the immunotherapy, nivolumab in people with advanced renal cell carcinoma (RCC). The trial is to be led by the Institut Gustave Roussy in Paris under the direction of Professor Bernard Escudier, […]

read more

NICE and NHS England plans to delay access to life-saving drugs

English charities warn that patients might have to wait three years for many life-extending new drugs if NHS England and the National Institute of Health and Care Excellence (NICE) enforce plans to allow the use of cost-effective medicines to be delayed, despite widespread opposition and a national petition. The charities warn that if the controversial rationing plans […]

read more

Sign the petition to stop NHS and NICE plans that would delay access to vital new cancer treatments

We urgently need your help to stop plans that would delay vital new drugs and treatments getting to patients. A final decision is expected in two weeks – make your voice heard today! NHS England and The National Institute for Health and Care Excellence (NICE) have put forward proposals, which threaten to have a devastating […]

read more

Patient selection is key for kidney cancer treatments

There are now a number of treatment options available for people with advanced kidney cancer as first- or second-line treatments. This article talks about the importance of keeping the patient’s characteristics and goals in mind when oncologists decide which treatment to use. “That gives you an idea of which agent to give to them and, […]

read more

Exercise better than drugs for cancer-related fatigue

A recent meta-analysis published in JAMA Oncology suggests that exercise and/or behavioural and educational therapy may be more effective than prescription drugs for dealing with cancer-related fatigue. The meta-analysis looked at 113 past studies that included 11,525 adult cancer patients, almost half of which were breast cancer patients. The analysis excluded studies that looked at complementary […]

read more

Savolitinib for papillary renal cell carcinoma

Papillary renal cell carcinoma (pRCC) is the second most common type of kidney cancer, but it is rare and very little is known about the biology of pRCC. However, a subset of patients with pRCC have an alteration (mutation) in the MET gene, which may be helpful in furthering the understanding of the disease. The […]

read more

Durable response after stopping immunotherapy for kidney cancer

A recent study presented at the American Society for Clinical Oncology (ASCO) 2017 Genitourinary Cancer Symposium held in Orlando, Florida last month, reported a sustained response to PD-1/PD-L1 immunotherapy in patients with metastatic renal cell carcinoma (RCC) who had stopped treatment due to immune-related adverse events. This durable response lasted for more than 6 months […]

read more

Vaccine trial for advanced kidney cancer recommended to be stopped

An independent data monitoring committee (IDMC) has recommended that the phase 3 ADAPT trial exploring rocapuldencel-T (AGS-003) for the first-line treatment of metastatic renal cell carcinoma (mRCC) be stopped because the trial is unlikely to show an improvement in overall survival. However, consistent with earlier phase 2 studies, rocapuldencel-T appears to be well tolerated.  The ADAPT trial recruited […]

read more

Obesity linked to 11 cancer types, including kidney cancer

A study published in the British Medical Journal (BMJ) and reported in The Times last week has found a strong link between obesity and a higher risk of developing cancer of the kidney, oesophagus, womb, ovary, bowel, stomach, multiple myeloma, rectum, biliary tract system, pancreas, and post-menopausal breast cancer. Researchers from Imperial College London conducted an ‘umbrella […]

read more

Patients have routine access to more cancer drugs as prices drop, according to NICE

The National Institute for Health and Care Excellence (NICE) reported last week that patients will have routine access to more cancer drugs as pharmaceutical companies reduce their prices as a result of being reconsidered by NICE in a new approach to the appraisal and funding of cancer drugs in England (a reformed Cancer Drugs Fund (CDF) […]

read more
Showing 1 to 10 of 67 results
  TOP